 MIAMI, Sept. 20, 2021 GLOBE NEWSWIRE -- Veru Inc. NASDAQ: VERU, an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that updated clinical data from the positive Phase 1b2 study of sabizabulin VERU-111 in 80 men with metastatic castration resistant prostate cancer who have progressed on at least one novel androgen receptor targeting agent were presented at the European Society for Medical Oncology ESMO Congress 2021 being held September 16-21, 2021. Sabizabulin is a new oral chemical entity that represents a novel class of agents that target unique binding sites on microtubules to disrupt both the cytoskeleton and androgen receptor transport. 